for patients with no known/suspected renal impairment (eGFR ≥90 mL/min) or mild renal impairment (eGFR ≥60 to <90 mL/min)
Days: 1-5
Dose: 2 nirmatrelvir 150 mg tablets (300 mg) + 1 ritonavir 100 mg tablet
Frequency: Twice daily*†
*PAXLOVID should be administered at approximately the same time each day for 5 days.
†Each dose should be taken approximately 12 hours apart, typically in the morning and at night.
for patients with moderate renal impairment (eGFR ≥30 to <60 mL/min)
Days: 1-5
Dose: 1 nirmatrelvir 150 mg tablet + 1 ritonavir 100 mg tablet
Frequency: Twice daily*†
*PAXLOVID should be administered at approximately the same time each day for 5 days.
†Each dose should be taken approximately 12 hours apart, typically in the morning and at night.
for patients with severe renal impairment (eGFR <30 mL/min), including those requiring hemodialysis‡
- Dose: 2 nirmatrelvir 150 mg tablets (300 mg) + 1 ritonavir 100 mg tablet
- Frequency: Once
Days 2-5:
- Dose: 1 nirmatrelvir 150 mg tablet + 1 ritonavir 100 mg tablet
- Frequency: Once daily
‡On days of hemodialysis, the PAXLOVID dose should be administered after hemodialysis.
PAXLOVID can be taken with or without food.
Download the Packaging and Dosing Guide here.
For patients with hepatic impairment
No dosage adjustment is recommended in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. PAXLOVID is not recommended for use in patients with severe (Child-Pugh Class C) hepatic impairment.
- Patients should begin treatment as soon as possible after a diagnosis of COVID-19 has been made, and it must be started within 5 days of symptom onset
- Patients should start with their evening dose if they receive their prescription after the morning
- If a patient loses a tablet, they should contact their healthcare provider and/or pharmacist
- Nirmatrelvir must be coadministered with ritonavir. Failure to correctly coadminister nirmatrelvir with ritonavir may result in plasma levels of nirmatrelvir that are insufficient to achieve the desired therapeutic effect
- Completion of the full 5-day treatment course and continued isolation in accordance with public health recommendations are important to maximize viral clearance and minimize transmission of SARS-CoV-2
- The tablets should be swallowed whole and not chewed, broken, or crushed
- If a patient misses a dose within 8 hours of the time it is usually taken, they should take it as soon as possible and resume the normal dosing schedule
- If a patient misses a dose by more than 8 hours, they should not take the missed dose and should instead take the next dose at the regularly scheduled time
- The patient should not double the dose to make up for a missed dose
- There is no specific antidote for overdose with PAXLOVID
- Treatment of overdose with PAXLOVID should consist of general supportive measures, including monitoring of vital signs and observation of the clinical status of the patient
Learn about PAXLOVID dosing recommendations and administration
Help patients understand PAXLOVID dosage and administration